



Onyx Pharmaceuticals, Inc.
3031 Research Dr.
Richmond, CA 94806
www.onyx-pharm.com
Tel. 510.222.9700
Fax 510.222.9758

Facsimile Transmittal Form

TO: Ex. Mosher

FROM: heg jett

DATE: 12/2/03

Number of Pages (including cover): 8

Comments:

Per our discussion, I'm faxing
a response* that was originally
faxed on 7/21/03

Thanks for your help
heg jett
* w/ extension of time & certificate
of transmission

WARNING: This facsimile message and accompanying documents are intended only for the use of the addressee indicated above. Information that is privileged or otherwise confidential may be contained therein. If you are not the intended recipient, you are hereby notified that any dissemination, copying, review or use of this message, documents or information contained therein is strictly prohibited. If you have received this message in error, please notify us immediately by telephone or facsimile and mail the original to us at the above address. Thank you.

HP LaserJet 3100
Printer/Fax/Copier/Scanner

SEND CONFIRMATION REPORT for
Onyx Pharmaceuticals
510-222-6767
Jul-21-03 6:06PM

OFFICIAL

Job	Start Time	Usage	Phone Number or ID	Type	Pages	Mode	Status
353	7/21 6:04PM	1'47"	USPTO	Send.....	7 / 7	EC144	Completed.....

Total 1'47" Pages Sent: 7 Pages Printed: 0

RECEIVED
CENTRAL FAX CENTER

DEC 02 2003

CERTIFICATE OF TRANSMISSION
UNDER 37 C.F.R. § 1.13

I hereby certify that this correspondence is being furnished to
Assistant Commissioner for Patents, Washington, DC 20231 at fax number 703-
388-6343 on July 21, 2003, by

Signature Date: 7/21/03

RESPONSE UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE - EXAMINING GROUP (1600)
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	PATENT APPLICATION
Inventor(s): Sylvio Laquerre)	
Terry Hermanson)	Art Unit: 1648
EC/Serial No.: 09/741, 127)	Examiner: Mosher, M.
Filed: December 18, 2000)	
Title: Herpes Simplex Virus 1 Glycoprotein)	
C Mutants for Treating Unwanted)	
Herpesvirus Infection Cell Growth)	

RESPONSE UNDER 37 C.F.R. § 1.116

Box AP
Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This RESPONSE is in reply to the Office action mailed April 18, 2003.

Onyx Pharmaceuticals
09/741, 127
amend 116

1